entertainment -WSS

entertainment

author：focus 2025-10-01 14:15:13 - browse：36138

Eli Lilly headquarters — Kristoffer Tripplaar/AP

SAN DIEGO – An experimental pill from Eli Lilly led to 14.7% weight loss on the highest dose in a 36-week trial, heating up the growing competition among drugmakers to develop an effective oral obesity therapy.

The mid-stage results for orforglipron match the estimates of 14-15% weight loss that Lilly gave in an investor call late last year. The full results, published Friday in the New England Journal of Medicine, were presented here to a packed conference room at the American Diabetes Association conference.

By the end of trial, the authors said, participants’ weight loss had not plateaued, suggesting potential for even greater weight loss over a longer treatment period.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： CVS Caremark has created a new ploy: the drug ‘rebate credit’

hotspot

WSS

Gene editing the human germline: What are the risks?

Intermittent fasting comes with a heart risk? Not so fast

Nurses recount patients attacks

Stop the failed accountable care organization experiment

Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources

AstraZeneca to buy developer of next

hotspot

entertainment

knowledge

United colonoscopy coverage change 'may cost lives,' doctors say

A new deal aims to ramp up use of AI in rehab care decisions

Hepatitis C has a cure — but many Americans still lack access to it

The biotech scorecard for the 2nd quarter: 12 industry events to watch

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

A former Republican legislative candidate has been charged for his role in the US Capitol riot

Alkermes shareholders re

Stop the failed accountable care organization experiment

The cancer drug shortage isn’t new — and neither are the solutions

Biden White House, tech companies launch new safeguards around emerging AI technology

hotspot

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Family of Gilgo Beach murder suspect releases statement: 'Devastating time'

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

AstraZeneca to buy developer of next

Positive childhood experiences can help future health

Neuroscience’s long legacy of racism

entertainment

hotspot

focus

explore